AU3245493A - Methods and compositions for treating hypertension, angina, and other disorders using optically pure s(-) felodipine - Google Patents

Methods and compositions for treating hypertension, angina, and other disorders using optically pure s(-) felodipine

Info

Publication number: AU3245493A
Authority: AU; Australia
Prior art keywords: felodipine; amount; composition according; administered; pharmaceutically acceptable
Prior art date: 1991-12-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU32454/93A

Other languages

English (en)

Inventor

James W. Young

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sunovion Pharmaceuticals Inc

Original Assignee

Sepracor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-02

Filing date

1992-12-01

Publication date

1993-06-28

1992-12-01 Application filed by Sepracor Inc filed Critical Sepracor Inc

1993-06-28 Publication of AU3245493A publication Critical patent/AU3245493A/en

Status Abandoned legal-status Critical Current

Links

RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 title claims description 136
229960003580 felodipine Drugs 0.000 title claims description 129
239000000203 mixture Substances 0.000 title claims description 94
238000000034 method Methods 0.000 title claims description 42
206010002383 Angina Pectoris Diseases 0.000 title claims description 20
206010020772 Hypertension Diseases 0.000 title claims description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 13
208000035475 disorder Diseases 0.000 title description 6
230000000694 effects Effects 0.000 claims description 54
230000002411 adverse Effects 0.000 claims description 36
150000003839 salts Chemical class 0.000 claims description 25
208000010125 myocardial infarction Diseases 0.000 claims description 14
238000011282 treatment Methods 0.000 claims description 14
206010003119 arrhythmia Diseases 0.000 claims description 13
206010019280 Heart failures Diseases 0.000 claims description 11
239000002775 capsule Substances 0.000 claims description 11
201000006474 Brain Ischemia Diseases 0.000 claims description 10
206010007572 Cardiac hypertrophy Diseases 0.000 claims description 10
208000006029 Cardiomegaly Diseases 0.000 claims description 10
206010008120 Cerebral ischaemia Diseases 0.000 claims description 10
230000006793 arrhythmia Effects 0.000 claims description 10
230000009460 calcium influx Effects 0.000 claims description 10
206010008118 cerebral infarction Diseases 0.000 claims description 10
238000002560 therapeutic procedure Methods 0.000 claims description 10
208000009304 Acute Kidney Injury Diseases 0.000 claims description 9
206010003225 Arteriospasm coronary Diseases 0.000 claims description 9
208000033626 Renal failure acute Diseases 0.000 claims description 9
206010062237 Renal impairment Diseases 0.000 claims description 9
201000011040 acute kidney failure Diseases 0.000 claims description 9
208000012998 acute renal failure Diseases 0.000 claims description 9
230000003276 anti-hypertensive effect Effects 0.000 claims description 9
201000011634 coronary artery vasospasm Diseases 0.000 claims description 9
239000003937 drug carrier Substances 0.000 claims description 9
208000006673 asthma Diseases 0.000 claims description 8
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 8
238000001990 intravenous administration Methods 0.000 claims description 8
206010007559 Cardiac failure congestive Diseases 0.000 claims description 7
208000018152 Cerebral disease Diseases 0.000 claims description 7
208000003890 Coronary Vasospasm Diseases 0.000 claims description 7
208000019695 Migraine disease Diseases 0.000 claims description 7
208000010877 cognitive disease Diseases 0.000 claims description 7
206010027175 memory impairment Diseases 0.000 claims description 7
206010027599 migraine Diseases 0.000 claims description 7
208000012322 Raynaud phenomenon Diseases 0.000 claims description 6
238000009472 formulation Methods 0.000 claims description 6
208000024827 Alzheimer disease Diseases 0.000 claims description 5
206010006482 Bronchospasm Diseases 0.000 claims description 5
208000009079 Bronchial Spasm Diseases 0.000 claims description 4
208000014181 Bronchial disease Diseases 0.000 claims description 4
238000001802 infusion Methods 0.000 claims description 4
230000003257 anti-anginal effect Effects 0.000 claims description 3
230000037317 transdermal delivery Effects 0.000 claims 3
229940127291 Calcium channel antagonist Drugs 0.000 description 24
150000001875 compounds Chemical class 0.000 description 24
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
239000003826 tablet Substances 0.000 description 15
239000004480 active ingredient Substances 0.000 description 14
239000003814 drug Substances 0.000 description 13
208000024891 symptom Diseases 0.000 description 13
206010012289 Dementia Diseases 0.000 description 12
230000000747 cardiac effect Effects 0.000 description 12
229940079593 drug Drugs 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
102000004877 Insulin Human genes 0.000 description 10
108090001061 Insulin Proteins 0.000 description 10
229940125396 insulin Drugs 0.000 description 10
238000012360 testing method Methods 0.000 description 10
239000011575 calcium Substances 0.000 description 9
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
230000036772 blood pressure Effects 0.000 description 8
229910052791 calcium Inorganic materials 0.000 description 8
239000000480 calcium channel blocker Substances 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
201000010099 disease Diseases 0.000 description 7
239000007788 liquid Substances 0.000 description 7
-1 S(-) felodipine isomer Chemical class 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
208000002173 dizziness Diseases 0.000 description 6
230000002526 effect on cardiovascular system Effects 0.000 description 6
206010016256 fatigue Diseases 0.000 description 6
210000004165 myocardium Anatomy 0.000 description 6
230000003389 potentiating effect Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
238000011699 spontaneously hypertensive rat Methods 0.000 description 6
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 5
241000700199 Cavia porcellus Species 0.000 description 5
208000000059 Dyspnea Diseases 0.000 description 5
206010013975 Dyspnoeas Diseases 0.000 description 5
206010019233 Headaches Diseases 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
206010030113 Oedema Diseases 0.000 description 5
230000004872 arterial blood pressure Effects 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
210000003414 extremity Anatomy 0.000 description 5
231100000869 headache Toxicity 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
239000008101 lactose Substances 0.000 description 5
239000001301 oxygen Substances 0.000 description 5
229910052760 oxygen Inorganic materials 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
239000000843 powder Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
230000002792 vascular Effects 0.000 description 5
208000037157 Azotemia Diseases 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
206010022489 Insulin Resistance Diseases 0.000 description 4
208000002193 Pain Diseases 0.000 description 4
201000001068 Prinzmetal angina Diseases 0.000 description 4
230000009471 action Effects 0.000 description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
238000007906 compression Methods 0.000 description 4
230000006835 compression Effects 0.000 description 4
230000008602 contraction Effects 0.000 description 4
239000008103 glucose Substances 0.000 description 4
230000006377 glucose transport Effects 0.000 description 4
239000008187 granular material Substances 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
238000007726 management method Methods 0.000 description 4
210000002464 muscle smooth vascular Anatomy 0.000 description 4
239000000725 suspension Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
208000000044 Amnesia Diseases 0.000 description 3
208000026139 Memory disease Diseases 0.000 description 3
241000700159 Rattus Species 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
229940030600 antihypertensive agent Drugs 0.000 description 3
239000002220 antihypertensive agent Substances 0.000 description 3
210000000709 aorta Anatomy 0.000 description 3
230000027455 binding Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000035487 diastolic blood pressure Effects 0.000 description 3
230000003205 diastolic effect Effects 0.000 description 3
230000003292 diminished effect Effects 0.000 description 3
238000011010 flushing procedure Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
230000001771 impaired effect Effects 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
208000028867 ischemia Diseases 0.000 description 3
230000006984 memory degeneration Effects 0.000 description 3
208000023060 memory loss Diseases 0.000 description 3
208000031225 myocardial ischemia Diseases 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
230000036515 potency Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000033764 rhythmic process Effects 0.000 description 3
208000013220 shortness of breath Diseases 0.000 description 3
210000002460 smooth muscle Anatomy 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
230000035488 systolic blood pressure Effects 0.000 description 3
230000002861 ventricular Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
206010003175 Arterial spasm Diseases 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
241000700198 Cavia Species 0.000 description 2
206010011224 Cough Diseases 0.000 description 2
206010012758 Diastolic hypertension Diseases 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
206010061216 Infarction Diseases 0.000 description 2
239000012839 Krebs-Henseleit buffer Substances 0.000 description 2
235000019759 Maize starch Nutrition 0.000 description 2
208000007101 Muscle Cramp Diseases 0.000 description 2
206010028813 Nausea Diseases 0.000 description 2
206010030124 Oedema peripheral Diseases 0.000 description 2
206010030302 Oliguria Diseases 0.000 description 2
206010037368 Pulmonary congestion Diseases 0.000 description 2
206010037423 Pulmonary oedema Diseases 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
206010042957 Systolic hypertension Diseases 0.000 description 2
208000001871 Tachycardia Diseases 0.000 description 2
206010047163 Vasospasm Diseases 0.000 description 2
208000012886 Vertigo Diseases 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
230000003143 atherosclerotic effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000003727 cerebral blood flow Effects 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000006735 deficit Effects 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 2
230000000004 hemodynamic effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000007574 infarction Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000000297 inotrophic effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
229960004427 isradipine Drugs 0.000 description 2
230000003907 kidney function Effects 0.000 description 2
210000005240 left ventricle Anatomy 0.000 description 2
208000013433 lightheadedness Diseases 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
238000000465 moulding Methods 0.000 description 2
230000002107 myocardial effect Effects 0.000 description 2
230000008693 nausea Effects 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
229960001597 nifedipine Drugs 0.000 description 2
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
238000010606 normalization Methods 0.000 description 2
239000003921 oil Substances 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
208000005333 pulmonary edema Diseases 0.000 description 2
238000011160 research Methods 0.000 description 2
210000002027 skeletal muscle Anatomy 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
230000000707 stereoselective effect Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000002889 sympathetic effect Effects 0.000 description 2
206010042772 syncope Diseases 0.000 description 2
230000006794 tachycardia Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
231100000889 vertigo Toxicity 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 1
PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
HMJIYCCIJYRONP-INIZCTEOSA-N 3-o-methyl 5-o-propan-2-yl (4s)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-INIZCTEOSA-N 0.000 description 1
208000010444 Acidosis Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000037259 Amyloid Plaque Diseases 0.000 description 1
206010002388 Angina unstable Diseases 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
206010069729 Collateral circulation Diseases 0.000 description 1
206010011091 Coronary artery thrombosis Diseases 0.000 description 1
206010011703 Cyanosis Diseases 0.000 description 1
206010016759 Flat affect Diseases 0.000 description 1
206010016807 Fluid retention Diseases 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
208000033830 Hot Flashes Diseases 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
208000002682 Hyperkalemia Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
206010021036 Hyponatraemia Diseases 0.000 description 1
206010021137 Hypovolaemia Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000000060 Migraine with aura Diseases 0.000 description 1
208000009233 Morning Sickness Diseases 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
208000008457 Neurologic Manifestations Diseases 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
206010033546 Pallor Diseases 0.000 description 1
206010033557 Palpitations Diseases 0.000 description 1
206010033864 Paranoia Diseases 0.000 description 1
208000027099 Paranoid disease Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
206010036631 Presenile dementia Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010063897 Renal ischaemia Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
206010049418 Sudden Cardiac Death Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
206010047295 Ventricular hypertrophy Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
208000034850 Vomiting in pregnancy Diseases 0.000 description 1
206010047924 Wheezing Diseases 0.000 description 1
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000007950 acidosis Effects 0.000 description 1
208000026545 acidosis disease Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000674 adrenergic antagonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229960000528 amlodipine Drugs 0.000 description 1
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
230000002978 anti-vasoconstrictor Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
230000037007 arousal Effects 0.000 description 1
230000008321 arterial blood flow Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
150000007657 benzothiazepines Chemical class 0.000 description 1
230000003851 biochemical process Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
150000001669 calcium Chemical class 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
230000003684 cardiac depression Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000004087 circulation Effects 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
238000013329 compounding Methods 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
230000009989 contractile response Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
208000026758 coronary atherosclerosis Diseases 0.000 description 1
208000002528 coronary thrombosis Diseases 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
230000000916 dilatatory effect Effects 0.000 description 1
230000010339 dilation Effects 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000428 dust Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
230000001434 glomerular Effects 0.000 description 1
238000007446 glucose tolerance test Methods 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
230000010247 heart contraction Effects 0.000 description 1
230000004217 heart function Effects 0.000 description 1
208000018578 heart valve disease Diseases 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000004041 inotropic agent Substances 0.000 description 1
230000003933 intellectual function Effects 0.000 description 1
201000004332 intermediate coronary syndrome Diseases 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
208000012947 ischemia reperfusion injury Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
210000005246 left atrium Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003908 liver function Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
206010052787 migraine without aura Diseases 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000002682 neurofibrillary tangle Anatomy 0.000 description 1
229960005366 nilvadipine Drugs 0.000 description 1
229960000715 nimodipine Drugs 0.000 description 1
229960000227 nisoldipine Drugs 0.000 description 1
229960005425 nitrendipine Drugs 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
238000003305 oral gavage Methods 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
239000000106 platelet aggregation inhibitor Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
230000034918 positive regulation of cell growth Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
208000023482 precordial pain Diseases 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000007425 progressive decline Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
239000008213 purified water Substances 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
208000037921 secondary disease Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
230000035807 sensation Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
208000018316 severe headache Diseases 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
210000001013 sinoatrial node Anatomy 0.000 description 1
230000016160 smooth muscle contraction Effects 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
231100000462 teratogen Toxicity 0.000 description 1
239000003439 teratogenic agent Substances 0.000 description 1
229960003433 thalidomide Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
208000003663 ventricular fibrillation Diseases 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU32454/93A 1991-12-02 1992-12-01 Methods and compositions for treating hypertension, angina, and other disorders using optically pure s(-) felodipine Abandoned AU3245493A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US80131691A	1991-12-02	1991-12-02
US801316		1991-12-02

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU22214/97A Division AU2221497A (en)	1991-12-02	1997-05-16	Methods and compositions for treating hypertension, angina, and other disorders using optically pure S(-) felodipine

Publications (1)

Publication Number	Publication Date
AU3245493A true AU3245493A (en)	1993-06-28

Family

ID=25180776

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AU32454/93A Abandoned AU3245493A (en)	1991-12-02	1992-12-01	Methods and compositions for treating hypertension, angina, and other disorders using optically pure s(-) felodipine
AU22214/97A Abandoned AU2221497A (en)	1991-12-02	1997-05-16	Methods and compositions for treating hypertension, angina, and other disorders using optically pure S(-) felodipine

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AU22214/97A Abandoned AU2221497A (en)	1991-12-02	1997-05-16	Methods and compositions for treating hypertension, angina, and other disorders using optically pure S(-) felodipine

Country Status (5)

Country	Link
EP (1)	EP0661971A1 (fr)
JP (1)	JPH07501551A (fr)
AU (2)	AU3245493A (fr)
CA (1)	CA2125149A1 (fr)
WO (1)	WO1993010781A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9501773D0 (sv) *	1995-05-15	1995-05-15	Astra Ab	New use
US7018649B2 (en)	2000-10-23	2006-03-28	Euro-Celtique, S.A.	Felodipine transdermal device and methods
AU2002232755A1 (en) *	2000-10-23	2002-05-06	Euroceltique S.A.	Felodipine transdermal device and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE429652B (sv) *	1978-06-30	1983-09-19	Haessle Ab	2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester
EP0287828A1 (fr) *	1987-03-27	1988-10-26	Byk Gulden Lomberg Chemische Fabrik GmbH	Produits intermédiaires et leur préparation
IT1230752B (it) *	1989-02-17	1991-10-29	Boehringer Biochemia Srl	Processo per la preparazione di 1,4 diidropiridine polisostituite in forma enantiomericamente pura.

1992
- 1992-12-01 CA CA002125149A patent/CA2125149A1/fr not_active Abandoned
- 1992-12-01 WO PCT/US1992/010630 patent/WO1993010781A1/fr not_active Application Discontinuation
- 1992-12-01 AU AU32454/93A patent/AU3245493A/en not_active Abandoned
- 1992-12-01 JP JP5510392A patent/JPH07501551A/ja active Pending
- 1992-12-01 EP EP93900984A patent/EP0661971A1/fr not_active Ceased
1997
- 1997-05-16 AU AU22214/97A patent/AU2221497A/en not_active Abandoned

Also Published As

Publication number	Publication date
WO1993010781A1 (fr)	1993-06-10
EP0661971A4 (fr)	1995-02-09
AU2221497A (en)	1997-07-31
EP0661971A1 (fr)	1995-07-12
JPH07501551A (ja)	1995-02-16
CA2125149A1 (fr)	1993-06-10

Publication	Publication Date	Title
US6291490B1 (en)	2001-09-18	Methods and compositions for treating conditions caused by excessive calcium influx in cells using optically pure (-) amlodipine
AU3147593A (en)	1993-06-28	Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
EP0658110B1 (fr)	1999-12-15	Utilisation du norastemizole pour le traitement de rhinite allergiques
US5508279A (en)	1996-04-16	Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia
US5834496A (en)	1998-11-10	Methods for treating hypertension using optically pure S(-) felodipine
US5571827A (en)	1996-11-05	Methods and compositions for treating hypertension, angina and other disorders using optically pure s(-) nitrendipine
AU3245493A (en)	1993-06-28	Methods and compositions for treating hypertension, angina, and other disorders using optically pure s(-) felodipine
AU1016900A (en)	2000-03-23	Methods and compositions for treating hypertension, angina, and other disorders using optically pures(-) felodipine
AU1354000A (en)	2000-03-30	Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
AU2006200150A1 (en)	2006-02-02	Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
EP1614420A2 (fr)	2006-01-11	Traitment de l'hypertension, de l'angine de poitrine et d'autres troubles avec (-)amlodipine
HK1029521A (en)	2001-04-06	Method and compositions for treating hypertensioin, angina and other disorders using optically pure (-) amlodipine.
US6110927A (en)	2000-08-29	Loratadine for use as an antiarrhythmic
US5510352A (en)	1996-04-23	Methods of using (+) doxazosin for the treatment of hypertension
AU711231B2 (en)	1999-10-07	Methods and compositions for treating hypertension, angina and other disorders using optically pure S(-) nitrendipine
WO1994007476A1 (fr)	1994-04-14	Procedes et compositions permettant de traiter l'hypertenson, les angines et d'autres affections au moyen de nitredipine s(-) optiquement pure
WO1994009783A1 (fr)	1994-05-11	Procedes et compositions contenant de la doxazosine (-) utilises dans le traitement de l'adenome prostatique et de l'atherosclerose
AU7252700A (en)	2001-03-15	Use of norastemizole for the treatment of allergic disorders